After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only postpartum depression pill approved in the United States.

Sage and partner Biogen (BIIB) eventually submitted a rolling New Drug Application for 217 in MDD and postpartum depression, in 2023, but the FDA granted approval in the latter indication only.

Astellas Pharma Inc. recently created a new role — that of chief research & development officer — and named Cambridge ...

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.

Parts of the Jacob Lake area are under GO evacuation orders, and the North Rim of the Grand Canyon is also evacuating. The fire has grown to 19,573 acres.

The Food and Drug Administration has approved a first of its kind, once-yearly shot designed to protect dogs from fleas and ...